8-KMaterial AgreementsFinancial Events

ABBOTT LABORATORIES 8-K Report, Material Agreement (Nov 30, 2018)

Filed November 30, 2018For Securities:ABT

Summary

Abbott Laboratories (ABT) announced the entry into a new Five Year Credit Agreement on November 29, 2018, replacing its previous credit facility. This new agreement provides the company with access to a $5 billion unsecured revolving credit line. Importantly, there were no outstanding borrowings under either the new or the terminated existing agreement at the time of the filing. The termination of the prior credit agreement, dated July 10, 2014, was a procedural step executed concurrently with the establishment of the new facility. The new agreement features similar terms to the old one, including interest rates tied to base or Eurodollar rates plus an applicable margin, and standard covenants and events of default. This action demonstrates Abbott's proactive approach to managing its liquidity and financial flexibility.

Key Highlights

  • 1Abbott Laboratories entered into a new $5 billion unsecured Five Year Credit Agreement.
  • 2The new credit facility became effective on November 29, 2018.
  • 3The agreement provides significant borrowing capacity to support ongoing operations and strategic initiatives.
  • 4There were no outstanding borrowings under the new credit agreement at the time of filing.
  • 5The new agreement replaced a previous Five Year Credit Agreement dated July 10, 2014.
  • 6The previous credit agreement also had a $5 billion unsecured revolving credit line.
  • 7No borrowings were outstanding under the previous agreement prior to its termination.

Frequently Asked Questions

This 8-K filing primarily announces Abbott Laboratories' entry into a new $5 billion unsecured Five Year Credit Agreement and the termination of its previous credit agreement. It is a routine disclosure regarding material definitive agreements and the creation of financial obligations.

No, the filing explicitly states that as of the date of the report, there were no outstanding borrowings under the new Revolving Credit Agreement.

The new Five Year Credit Agreement allows Abbott to borrow up to $5 billion on an unsecured basis. Borrowings will mature on the fifth anniversary of the effective date and will bear interest based on a base rate or Eurodollar rate, plus an applicable margin determined by Abbott's credit ratings. It also includes customary covenants and events of default.

Abbott terminated the existing credit agreement as a concurrent action to entering into the new Five Year Credit Agreement. This is a standard procedure when establishing a new credit facility to consolidate or update financing arrangements.